Rankings / Hormones & Endocrine
Romosozumab (Evenity)
Hormones & Endocrine · Sclerostin antibody (bone anabolic)
Tier B
Bottom line
Read Off Label grades Romosozumab (Evenity) as B (6.5/10) based on strong evidence, very high for bone benefit magnitude, and a med-high-risk safety profile.
Amgen/UCB.
Typical use: 210 mg SC monthly (two 105 mg injections at one visit) for 12 doses; followed by antiresorptive (bisphosphonate or… — Rx.
What this is
Amgen/UCB. Most potent bone-anabolic drug to date. The 12-month course produces gains comparable to several years of teriparatide. CV warning is the practical limiter — patients with recent MI/stroke excluded. Important for biohacker bone-density obsession given that bone loss is heavily emphasized by Peter Attia and others. ARCH 2017 showed CV signal vs alendronate; subsequent meta-analyses are mixed — class-wide caution remains.
Mechanism
Humanized monoclonal antibody binds and neutralizes sclerostin (SOST), the osteocyte-secreted Wnt-pathway inhibitor; concurrently increases bone formation AND decreases bone resorption (uniquely 'dual action' vs other osteoporosis drugs); 12-month treatment course
Dose & route
210 mg SC monthly (two 105 mg injections at one visit) for 12 doses; followed by antiresorptive (bisphosphonate or denosumab)
Citations
- https://pubmed.ncbi.nlm.nih.gov/27641143/
- https://pubmed.ncbi.nlm.nih.gov/28892457/
- https://pubmed.ncbi.nlm.nih.gov/39579023/
- https://clinicaltrials.gov/study/NCT00896532
- https://pubmed.ncbi.nlm.nih.gov/41303575/
Links go to the source. If a link is dead or you want something re-checked, let me know.
Common questions
- Does Romosozumab (Evenity) work?
- Read Off Label rates the evidence for Romosozumab (Evenity) as Strong and the benefit magnitude as very high for bone, producing an overall grade of B (6.5/10). Amgen/UCB.
- Is Romosozumab (Evenity) safe?
- Romosozumab (Evenity) has a med-high risk profile in published human data. Legal status: Rx (FDA-approved 2019 for postmenopausal osteoporosis at high fracture risk). This is not medical advice — see the disclaimer.
- What is the typical dose for Romosozumab (Evenity)?
- 210 mg SC monthly (two 105 mg injections at one visit) for 12 doses; followed by antiresorptive (bisphosphonate or denosumab)
- How does Romosozumab (Evenity) work?
- Humanized monoclonal antibody binds and neutralizes sclerostin (SOST), the osteocyte-secreted Wnt-pathway inhibitor; concurrently increases bone formation AND decreases bone resorption (uniquely 'dual action' vs other osteoporosis drugs); 12-month treatment course
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.